IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.227
EU - Europa 3.989
AS - Asia 3.865
Continente sconosciuto - Info sul continente non disponibili 487
SA - Sud America 428
AF - Africa 67
OC - Oceania 12
Totale 17.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.020
SG - Singapore 1.454
CN - Cina 1.147
IT - Italia 708
UA - Ucraina 533
IE - Irlanda 508
GB - Regno Unito 469
RU - Federazione Russa 398
TR - Turchia 370
SE - Svezia 368
VN - Vietnam 366
BR - Brasile 345
FR - Francia 343
DE - Germania 236
FI - Finlandia 141
IN - India 134
PL - Polonia 127
CA - Canada 101
BD - Bangladesh 99
HK - Hong Kong 77
MX - Messico 46
JP - Giappone 35
ES - Italia 33
ZA - Sudafrica 31
AR - Argentina 30
SA - Arabia Saudita 28
CZ - Repubblica Ceca 27
BE - Belgio 24
IQ - Iraq 21
KR - Corea 20
ID - Indonesia 19
NL - Olanda 19
JM - Giamaica 16
AT - Austria 15
LT - Lituania 14
PK - Pakistan 14
AE - Emirati Arabi Uniti 12
EC - Ecuador 12
CO - Colombia 11
UZ - Uzbekistan 11
VE - Venezuela 10
IR - Iran 9
MA - Marocco 9
AU - Australia 8
PH - Filippine 8
CL - Cile 7
HN - Honduras 7
CR - Costa Rica 6
GT - Guatemala 6
MY - Malesia 6
BY - Bielorussia 5
EU - Europa 5
GP - Guadalupe 5
JO - Giordania 5
LY - Libia 5
NI - Nicaragua 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
CW - ???statistics.table.value.countryCode.CW??? 4
DZ - Algeria 4
EG - Egitto 4
KE - Kenya 4
NP - Nepal 4
PS - Palestinian Territory 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
UY - Uruguay 4
CH - Svizzera 3
GR - Grecia 3
IL - Israele 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
OM - Oman 3
PE - Perù 3
PR - Porto Rico 3
PT - Portogallo 3
SV - El Salvador 3
BN - Brunei Darussalam 2
EE - Estonia 2
GA - Gabon 2
HU - Ungheria 2
LB - Libano 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GY - Guiana 1
HR - Croazia 1
NG - Nigeria 1
NO - Norvegia 1
Totale 16.596
Salva come PNG Salva come JPEG
Città #
Singapore 1.074
San Jose 845
Chandler 662
Jacksonville 585
Ashburn 540
Dublin 499
Dallas 399
Southend 312
Beijing 291
Council Bluffs 290
Princeton 220
Los Angeles 205
Dearborn 182
Izmir 170
Nanjing 155
New York 128
Ho Chi Minh City 117
Santa Clara 107
Wilmington 102
Kraków 98
Cambridge 96
Hanoi 91
Chieti 89
Tongling 84
Altamura 79
Buffalo 77
Hong Kong 72
Phoenix 71
The Dalles 71
Ann Arbor 67
Nanchang 64
Boardman 57
Munich 50
Washington 50
Denver 47
Moscow 44
Rome 44
Columbus 43
Orem 42
Shenyang 42
Atlanta 41
São Paulo 41
San Francisco 39
Woodbridge 38
Brooklyn 36
Pescara 36
Montreal 34
North Bergen 34
Redondo Beach 34
Chicago 33
Houston 30
Seattle 30
Changsha 29
Hebei 29
Tianjin 29
Hefei 28
Grevenbroich 27
Helsinki 27
Warsaw 27
Jiaxing 25
Tokyo 25
Milan 23
Riyadh 23
Brno 22
Brussels 21
Kocaeli 21
Hangzhou 20
Johannesburg 20
Kunming 20
Camerino 19
Kimball 19
St Louis 19
Toronto 19
Boston 18
Mexico City 18
Seoul 18
Shanghai 18
Orange 17
Norwalk 16
Spoltore 16
Da Nang 15
Manchester 15
Nuremberg 15
Poplar 15
Lappeenranta 14
London 14
Stockholm 14
Belo Horizonte 13
Chennai 13
Claxton 13
Jinan 13
Mumbai 13
Ankara 12
Düsseldorf 12
Haiphong 12
Newark 12
Vancouver 12
Frankfurt am Main 11
Guangzhou 11
Leawood 11
Totale 9.560
Salva come PNG Salva come JPEG
Nome #
Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease 616
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 432
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 408
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 370
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 254
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 207
Antithrombotic Agents and Cancer 189
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 184
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 182
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 179
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 177
Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained 171
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 171
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 169
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 167
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 167
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 162
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 162
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 159
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 155
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 152
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 151
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 149
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 148
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 146
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 144
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 142
New insights into COX-2 biology and inhibition. 141
Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity 140
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 140
Platelet activation in patients with colorectal cancer. 140
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 140
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 139
Clinical pharmacology of selective COX-2 inhibitors. 138
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 137
Determinants of platelet activation in human essential hypertension. 137
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 135
Oxidative stress and platelet activation in essential hyperytension 135
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 135
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 135
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 134
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 134
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 133
Mechanistic and pharmacological issues of aspirin as an anticancer agent 133
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 132
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 132
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 132
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 131
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 131
Risk management profile of etoricoxib: An example of personalized medicine 131
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 130
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 129
Clinical pharmacology of novel selective COX-2 inhibitors. 129
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 129
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 129
Gut microbiota, host gene expression, and aging. 129
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 129
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 128
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 128
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 127
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 127
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 127
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 126
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 126
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 126
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 125
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 124
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 124
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A2 receptor 123
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 123
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 123
NSAIDs and cardiovascular disease. 123
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 122
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 118
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 118
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 118
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 117
Clinical pharmacology of etoricoxib. 117
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 117
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 116
Pharmacodynamic of cyclooxygenase inhibitors in humans. 115
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 115
Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention 113
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 113
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 112
Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro 112
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 111
Cyclooxygenases and platelet functions 110
P2Y12 Receptors in Tumorigenesis and Metastasis 110
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 108
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. 108
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 107
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 106
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 106
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 105
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 104
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 104
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 104
Evaluating plasma vesicle signatures in chronic coronary artery disease patients for tailored dual therapy with low-dose rivaroxaban and aspirin 102
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 102
Totale 14.722
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.742
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022457 0 0 0 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/20265.617 443 250 526 672 471 307 829 328 558 430 315 488
2026/20272.416 332 631 759 694 0 0 0 0 0 0 0 0
Totale 17.075